Source: International Congress 2015 – The immunology of allergic airway disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Irene Heijink (Groningen, Netherlands), Irene Heijink, Marnix Jonker, Dirkje Postma, Maarten Van den Berge. Differential effects of budesonide and fluticasone propionate on immune defense genes in human bronchial epithelium. Eur Respir J 2015; 46: Suppl. 59, 2558

Member's Comments

No comment yet.

Related content which might interest you: Differential effects of budesonide and fluticasone propionate on bacterial recognition receptors in COPD macrophages Source: International Congress 2016 – Airway response to infection Year: 2016 Differential effects of budesonide and fluticasone propionate on expression of lactotransferrin in airway epithelium Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Differential effects of budesonide and fluticasone propionate on bronchial epithelial barrier function Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Budesonide and fluticasone propionate exertdifferential effects on human bronchial epithelial cells exposed to streptococcus pneumoniae and viral mimetic Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Differential effect of fluticasone on Poly(I:C) induced TSLP secretion by bronchial epithelial cells from asthmatic children Source: International Congress 2016 – Mechanisms of disease Year: 2016 Fluticasone propionate reduces bacterial airway epithelial invasion Source: Eur Respir J 2008; 32: 1283-1288 Year: 2008 Initial interaction of fluticasone propionate with ciliated respiratory epithelium Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Comparison of fluticasone propionate and budesonide on phagocytosis of common respiratory pathogens in COPD patients Source: Annual Congress 2011 - Immunology and cell biology of asthma and COPD Year: 2011 Comparison of budesonide and fluticasone propionate on COPD macrophage phagocytosis and killing of bacteria Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Response to fluticasone propionate in controlling airway inflammation in steroid-naïve asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 317s Year: 2006 Multiple synergistic effects of fluticasone propionate and salmeterol on T-cell activation in bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 250s Year: 2004 Nasal fibroblast functions involved in airway inflammation and remodelling are downregulated by fluticasone propionate (FP) Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001 Tiotropium and fluticasone inhibit rhinovirus-induced mucin production via multiple mechanisms in differentiated airway epithelial cells Source: Virtual Congress 2020 – Host-microbe interactions and their influence on lung disease onset and severity Year: 2020 Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005 Effects of mometasone and formoterol on the innate immunity of human gingival epithelial cells Source: International Congress 2017 – Infection and exacerbation science Year: 2017 Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma Source: Eur Respir J 2002; 20: 66-72 Year: 2002 Evaluation of the effect of inhaled ciclesonide on inflammatory and allergic markers and pulmonary function in bronchial asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Anticholinergic treatment does not affect toll-like receptor 3-induced antiviral immune response in COPD bronchial epithelial cells Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008 Anti-inflammatory effect of the combination of a long acting β2-agonist (salmeterol) and a corticosteroid (fluticasone propionate) on human airway epithelial cells following staphylococcus aureus virulence factors challenge Source: Eur Respir J 2006; 28: Suppl. 50, 104s Year: 2006